AstraZeneca
capital allocation capital allocation strategy unchanged investments to drive future growth reinvestment in the business free post currently projects in phase development investments behind launches in new indications and strengthening leadership in existing therapy areas continued investments in new technologies and platforms including cell and gene therapies progressive dividend policy value accretive deals continue to leverage partnerships to drive innovation and bring medicines to markets priority remains in our business new approvals in major markets | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
November 2023
Slide
12 of 45
Related slides by other companies
Pershing Square
Investor Presentation
February 2021
| Pershing Square
Morgan Stanley
Investor Presentation
January 2023
consistent strategic actions affirm our likes and dislikes acquisitions exits | Morgan Stanley
Compass Group
Results
November 2020
capital allocation priorities | Compass Group
eBay
Shareholder Engagement
May 2023
table of contents business strategy and capital allocation human capital des and global impact | eBay
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Results
November 2024
Investor Event
September 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights